Comparative analysis of serum galanin levels in patients with coronary artery disease with and without heart failure with reduced ejection fraction and in individuals without cardiovascular diseases
Yu. S. Timofeev,
A. A. Yafarova,
A. F. Sheptulina,
A. R. Kiselev,
V. A. Metelskaya,
N. I. Dubovskaya,
O. M. Drapkina https://doi.org/10.15829/1728-8800-2024-4156
EDN: XXPRVW
Abstract
Aim. To study the level of the neuro-regulatory peptide galanin in patients with coronary artery disease (CAD) with and without heart failure with reduced ejection fraction (HFrEF) in comparison with individuals without cardiovascular disease (CVD) included in the control group.
Material and methods. The study included 80 male patients as follows: 30 patients with CAD and HFrEF; 30 patients with CAD and without HFrEF; 20 individuals without CVD (control group). The groups were comparable in age and body mass index (BMI).
Results. The median (Me) age of patients with CAD and HFrEF was 67,5 years, while in individuals without CVD — 56,5 years. In the CAD and HFrEF group, 73,4% of patients had New York Heart Association (NYHA) class II HF. The galanin level was significantly (p<0,001) higher in patients with CAD with HFrEF (Me [Q25-Q75] — 84,5 [62,2-96,2] pg/ml) and CHD without CHFrEF (82,9 [68,2-94,0] pg/ml compared to the control group (53,0 [24,4-62,9] pg/ml). According to the ROC analysis, the highest area under the curve (AUC=0,924) for galanin was in the CAD without HFrEF group relative to the control. At the estimated threshold level of 71,5 pg/ml, the sensitivity and specificity were 70,0% and 95,0%, respectively.
Conclusion. The obtained results suggest an association between galanin and the pathophysiological mechanisms of CAD development, regardless of HFrEF.
Supporting agencies: The study was carried out within state assignment "Association of sarcopenia with metabolic disorders, chronic inflammation and changes in psychological status in obese patients" (2023-2025, registration number 123020600129-8).
About the Authors
Yu. S. Timofeev
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. A. Yafarova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. F. Sheptulina
National Medical Research Center for Therapy and Preventive Medicine; Russian University of Medicine
Russian Federation
Russian Federation
Moscow
A. R. Kiselev
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
V. A. Metelskaya
National Medical Research Center for Therapy and Preventive Medicine; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Moscow
N. I. Dubovskaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine; Russian University of Medicine
Russian Federation
Russian Federation
Moscow
References
1. Tatemoto K, Rökaeus A, Jörnvall H, et al. Galanin — a novel biologically active peptide from porcine intestine. FEBS Lett. 1983;164(1):124-8. doi:10.1016/0014-5793(83)80033-7.
2. Lang R, Gundlach AL, Holmes FE, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2015;67(1):118-75. doi:10.1124/pr.112.006536.
3. Li RY, Song HD, Shi WJ, et al. Galanin inhibits leptin expression and secretion in rat adipose tissue and 3T3L1 adipocytes, J Mol Endocrinol. 2004;33:1119. doi:10.1677/jme.0.0330011.
4. Waters SM, Krause JE. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience. 2000;95(1):265-71. doi:10.1016/s0306-4522(99)00407-8.
5. Webling KE, Runesson J, Bartfai T, et al. Galanin receptors and ligands. Front Endocrinol (Lausanne). 2012;3:146. doi:10.3389/fendo.2012.00146.
6. Šípková J, Kramariková I, Hynie S, et al. The galanin and galanin receptor subtypes, its regulatory role in the biological and pathological functions. Physiol Res. 2017;66(5):729-40. doi:10.33549/physiolres.933576.
7. Fang P, Sun J, Wang X, et al. Galanin participates in the functional regulation of the diabetic heart. Life Sci. 2013;92(11):628-32. doi:10.1016/j.lfs.2013.01.024.
8. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther. 2007;115(2): 177-207. doi:10.1016/j.pharmthera.2007.05.009.
9. Boal F, Cinato M, Timotin A, et al. Galanin Regulates Myocardial Mitochondrial ROS Homeostasis and Hypertrophic Remodeling Through GalR2. Front Pharmacol. 2022;13:869179. doi:10.3389/fphar.2022.869179.
10. Martinelli I, Timotin A, Moreno-Corchado P, et al. Galanin promotes autophagy and alleviates apoptosis in the hypertrophied heart through FoxO1 pathway. Redox Biol. 2021;40:101866. doi:10.1016/j.redox.2021.101866.
11. Abbott SB, Pilowsky PM. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):1019-26. doi:10.1152/ajpregu.90885.2008.
12. Studneva IM, Veselova OM, Bahtin AA, et al. The Mechanisms of Cardiac Protection Using a Synthetic Agonist of Galanin Receptors during Chronic Administration of Doxorubicin. Acta Naturae. 2020;12(1):89-98. (In Russ.) doi:10.32607/actanaturae.10945.
13. Dobrokhotov IV, Veselova OM, Lyubimov RO. Cardioprotective effect of galanin and its analogues on different experimental models of heart damage. Russian Cardiology Bulletin. 2021;16(4):11-6. (In Russ.) doi:10.17116/Cardiobulletin20211604111.
14. Studneva IM, Palkeeva ME, Veselova OM, et al. Protective action of a modified fragment of galanine in rats with doxorubicin-induced heart failure. Biomed Khim. 2019;65(1):51-6. (In Russ.) doi:10.18097/PBMC20196501051.
15. Yafarova AA, Kiselev AR, Sheptulina AF, et al. Modern ideas about the role of the galaninergic system in the pathogenesis of heart failure and myocardial remodeling. Cardiovascular Therapy and Prevention. 2023;22(5):3546. (In Russ.) doi:10.15829/1728-8800-2023-3546.
16. Zhang Z, Fang P, Yu M, et al. Serum Galanin Concentration is Increased in Subjects with Impaired Glucose Tolerance. Can J Diabetes. 2017;41(6):563-6. doi:10.1016/j.jcjd.2017.01.001.
17. Sandoval-Alzate H, Agudelo-Zapata Y, González-Clavijo A, et al. Serum Galanin Levels in Young Healthy Lean and Obese Non-Diabetic Men during an Oral Glucose Tolerance Test. Sci Rep. 2016;6:31661. doi:10.1038/srep31661.
18. Savchenko L, Kramar S, Todua N, et al. Galanin Coordinates Macrophage-Associated Fibro-Inflammatory Response and Mitochondrial Integrity in Myocardial Infarction Reperfusion Injury. Int J Mol Sci. 2024;25(11):6211. doi:10.3390/ijms25116211.
19. Özkaramanlı Gür D, Sağbaş M, Akyüz A, et al. Role of sympathetic cotransmitter galanin on autonomic balance in heart failure: an active player or a bystander? Anatol J Cardiol. 2017;18(4):281-8. doi:10.14744/AnatolJCardiol.2017.7831.
20. Öztürk Ö, Cebeci D, Şahin U, et al. Circulating levels of ghrelin, galanin, and orexin-A orexigenic neuropeptides in obstructive sleep apnea syndrome. Sleep Breath. 2022;26(3):1209-18. doi:10.1007/s11325-021-02514-w.
21. Kravchun PG, Kadykova OI, Herasymchuk US. Galanin levels in hypertensive patients with obesity. Wiad Lek. 2022;75(1):79-84. doi:10.36740/WLek202201115.
22. Alotibi MN, Alnoury AM, Alhozali AM. Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome. Relationships to insulin resistance and obesity. Saudi Med J. 2019; 40(1):19-25. doi:10.15537/smj.2019.1.22825.
23. Fang P, Yu M, Gu X, et al. Circulating galanin and galanin like peptide concentrations are correlated with increased triglyceride concentration in obese patients. Clin Chim Acta. 2016;461:126-9. doi:10.1016/j.cca.2016.07.019.
Supplementary files
What is already known about the subject?
- Galanin and its receptors play an important role in the regulation of the cardiovascular system. Galaninergic system activation leads to increased protective mechanisms of cardiomyocytes, improved carbohydrate metabolism, reduced oxidative stress and prevention of cardiomyocyte hypertrophy by suppressing the expression of certain genes.
- In pathological conditions, such as heart failure, there is sympathetic nervous system hyperactivation, accompanied by overexpression of the adrenergic co-transmitter galanin, the hypersecretion of which aggravates the autonomic imbalance, and also contributes to myocardial remodeling and heart failure (HF) progression.
What might this study add?
- For the first time, it was shown that the galanin level is significantly higher in patients with coronary artery disease, regardless of HF with a reduced ejection fraction, compared to individuals without cardiovascular diseases.
- The ROC analysis showed that galanin can be considered a potential diagnostic marker for the detection of coronary artery disease, regardless of HF with a reduced ejection fraction, demonstrating high diagnostic sensitivity and specificity compared to the control group.
Review
For citations:
Timofeev Yu.S., Yafarova A.A., Sheptulina A.F., Kiselev A.R., Metelskaya V.A., Dubovskaya N.I., Drapkina O.M. Comparative analysis of serum galanin levels in patients with coronary artery disease with and without heart failure with reduced ejection fraction and in individuals without cardiovascular diseases. Cardiovascular Therapy and Prevention. 2024;23(10):4156. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4156. EDN: XXPRVW
Views:
430
Email this article 
